NCT03900377 - Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

September 9, 2020

Study Completion Date

February 26, 2021

Conditions

Lymphoma, B-cell, Diffuse

Interventions

DRUG

SyB L-0501RI

The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.

Trial Locations (14)

Research Site, Nagoya

Research Site, Ōta

Research Site, Sapporo

Research Site, Kobe

Research Site, Isehara

Research Site, Kurashiki

Research Site, Koto-ku

Research Site, Akita

Research Site, Fukuoka

Research Site, Kagoshima

Research Site, Kumamoto

Research Site, Kyoto

Research Site, Okayama

Research Site, Yamagata